12:00 AM
 | 
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NBTXR3: Interim Phase I data

Interim data from 12 patients with STS in an open-label, dose-escalation, French Phase I trial showed that a single intratumoral injection of NBTXR3 was safe and led to no grade 3/4 adverse events. Nanobiotix also said that NBTXR3 "provided adequate distribution of nanoparticles within the tumor" for...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >